Encore Medical Education announces publication of the Official Best of SABCS(R) News Highlights summarizing key trial results from the 2022 SABCS(R)

Best of SABCS(R) News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide.

Encore Medical Education, a US-based medical education company will launch the 2022 edition of the Best of SABCS(R) News Highlights program from the 2022 San Antonio Breast Cancer Symposium (SABCS(R)) starting December 7th.

This official SABCS(R) News Highlights program reached more than 5,000 health care professionals in 2021 from over 50 countries. "Excellent recap of the wide variety of presentations from SABCS(R). This is such a dense conference that these summary presentations are almost mandatorysaid a user who registered in 2021 for program. "The presentations included in these highlights discuss hot scientific topics by experts in the field. The most updated findings are also provided giving great insights regarding the potential advancements in the clinical setting," said another registered user.

A stellar faculty will present their key takeaways with selected original slides from the major trials from #SABCS22 including:

  • Outcomes RxPONDER trial
  • An update of TAILORx trial
  • Primary results from the randomized Phase II RIGHT Choice  trial
  • Results from RIO-US B-12 TALENT trial
  • Results from the Phase III CAPItello-291  trial
  • Overall survival results from EMERALD
  • Results from multi-dose Phase 2 SERENA-2  trial
  • And many others…

The first expert video highlights will be available starting December 7th at 4PM Central Time (GMT -6 hours). Register today at https://bestofsabcsnews.com/#/home/register and to get daily updates on the most relevant advances in breast cancer via email.

The Best of SABCS(R) News Highlights is intended for all healthcare professionals including academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals.

About Best of SABCS(R) programs

The San Antonio Breast Cancer Symposium(R), now in its 45th year, is the premier conference for basic, translational, and clinical cancer research professionals

Best of SABCS(R) programs offer professionals the opportunity to experience and discuss the most current research and advances in the field of breast cancer with colleagues and key opinion leaders with access to the original presentations and posters.

For information on Best of SABCS(R) opportunities, please contact Encore Medical Education LLC at [email protected]

Video - https://www.youtube.com/watch?v=A49ituFmMVw&feature=youtu.be
Logo - https://mma.prnewswire.com/media/1959278/SABCS_Logo.jpg


ข่าวbreast cancer+Best of SABCSวันนี้

Encore Medical Education announces publication of the Official Best of SABCS(R) News Highlights summarizing key trial results from the 2022 SABCS(R)

Best of SABCS(R) News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide. Encore Medical Education, a US-based medical education company will launch the 2022 edition of the Best of SABCS(R) News Highlights program from the 2022 San Antonio Breast Cancer Symposium (SABCS(R) ) starting December 7th. This official SABCS(R) News Highlights program reached more than 5,000 health

Official Best of SABCS(R) News - 2020 SABCS(R) Highlights Coverage

The 43rd Virtual San Antonio Breast Cancer Symposium (SABCS(R)) is just one week away! Register now to the Official Best of SABCS(R) News 2020 program to get a daily update on the most relevant advances in breast cancer. Encore...

Cancer remains one of the most pressing h... AXA Strengthens Cancer Awareness and Prevention Efforts in Thailand — Cancer remains one of the most pressing health challenges in Thailand, with over 180...

Bangkok Dusit Medical Services Public Com... BDMS Launches Breast Cancer Screening Campaign to Promote Early Detection and Prevention — Bangkok Dusit Medical Services Public Company Limited (BDMS), a...

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection , securing exclusive commercialization licensing and supply of...

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor...

Mr. Poonsit Wongthawatchai (left), Krungs... Krungsri supports Breast Foundation in screening breast cancer for disadvantaged women for 14th year — Mr. Poonsit Wongthawatchai (left), Krungsri Executi...